<DOC>
	<DOCNO>NCT01327755</DOCNO>
	<brief_summary>Study Hypothesis : The addition selenium supplementation cotrimoxazole improve CD4 count , decrease opportunistic infection , decrease viral load delay need initiate antiretroviral therapy ( ART ) Rwandan adult patient infect HIV/ AIDS .</brief_summary>
	<brief_title>Rwanda Selenium Supplementation Clinical Trial</brief_title>
	<detailed_description>Patients recruit two health facility ( Kibagabaga District Hospital , Kinyinya Health Center Kigali ) , Rwanda offer care treatment HIV/AIDS patient . Patients recruit 3-4 month period . Consenting adults fit inclusion criterion enrol follow 2 year . Study assessment occur enrollment , 6 , 12 , 18 , 24 month initiation selenium supplementation . Participants randomize use simple randomized block design receive either cotrimoxazole selenium cotrimoxazole identically appear placebo take daily 2 year . Participants return clinic schedule follow home . All consent patient CD4 count 400 650 mm3 select similar immunological level hence eligible start ARV treatment study start . The study look efficacy selenium supplementation already compromise group patient similar stage disease .</detailed_description>
	<mesh_term>Selenium</mesh_term>
	<criteria>Patients &gt; = 21 year enrollment Confirmed HIV positive CD4 range 400 650 mm3 HIV+ patient willing participate study provide inform consent Preantiretroviral therapy ( PreART ) enrollment study ( yet initiate ART ) Willing practice barrier method birth control time Patients intend transfer clinic catchment area study end Patients scheduled start ART Moribund patient Pregnant woman Unable want commit barrier method birth control</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Selenium</keyword>
	<keyword>HIV/ AIDS</keyword>
	<keyword>CD4 count</keyword>
	<keyword>Antiretroviral therapy</keyword>
</DOC>